Study of ASP0739 Alone and With Pembrolizumab in Advanced Solid Tumors With NY-ESO-1 Expression Participants

NCT04939701 · clinicaltrials.gov ↗
PHASE1,PHASE2
Phase
TERMINATED
Status
16
Enrollment
INDUSTRY
Sponsor class

Stopped The comprehensive assessment of other studies indicated the lack of significant monotherapy activity, therefore, team decided to terminate the study.

Conditions

Interventions

Sponsor

Astellas Pharma Global Development, Inc.